You're tuned in to Markets Desk, let's get you up to speed.
Euronext is making a leadership change at the top, with the pan-European exchange operator announcing David Knibbe as its incoming chief executive, set to be formally nominated at the annual general meeting in May of two thousand twenty seven. Knibbe arrives from NN Group, where he has led the Dutch insurer since two thousand nineteen, signaling a finance-heavy background for the exchange's next chapter.
Turning to housing finance, the average analyst price target on Fannie Mae preferred stock has been slashed by nearly forty-eight percent, dropping from roughly thirty dollars and forty-four cents down to fifteen dollars and ninety-one cents. That is a dramatic downward revision that reflects deepening uncertainty around the GSE's capital structure and the ongoing ambiguity over its path out of conservatorship.
On the pharma side, Neuren Pharmaceuticals scored a meaningful regulatory milestone after the FDA granted orphan drug designation to its compound NNZ-two five nine one for neonatal hypoxic-ischemic encephalopathy, a serious condition affecting newborns deprived of oxygen at birth. Orphan status brings with it development incentives and a clearer regulatory pathway, which matters considerably for a rare disease program of this scale.
That's the tape. Markets Desk, signing off the floor.
